Positive inotropism in mammalian skeletal muscle in vitro during and after fatigue.
We tested the hypothesis that positive inotropic factors decrease fatigue and improve recovery from fatigue in mammalian skeletal muscle in vitro. To induce fatigue, we stimulated mouse soleus and extensor digitorum longus (EDL) to perform isometric tetanic contractions (50 impulses x s(-1) for 0.5 s) at 6 contractions x min(-1) for 60 min in soleus and 3 contractions x min(-1) for 20 min in EDL. Muscles were submerged in Krebs-Henseleit bicarbonate solution (Krebs) at 27 degrees C gassed with 95% nitrogen - 5% carbon dioxide (anoxia). Before and for 67 min after the fatigue period, muscles contracted at 0.6 contractions x min(-1) in 95% oxygen - 5% carbon dioxide (hyperoxia). We added a permeable cAMP analog (N6, 2'-O-dibutyryladenosine 3':5'-cyclic monophosphate at 10(-3) mol x L(-1) (dcAMP)), caffeine (2 x 10(-3) mol x L(-1), or Krebs as vehicle control at 25 min before, during, or at the end of the fatigue period. In soleus and EDL, both challenges added before fatigue significantly increased developed force but only caffeine increased developed force when added during the fatigue period. At the end of fatigue, the decrease in force in challenged muscles was equal to or greater than in controls so that the force remaining was the same or less than in controls. EDL challenged with dcAMP or caffeine at any time recovered more force than controls. In soleus, caffeine improved recovery except when added before fatigue. With dcAMP added to soleus, recovery was better after challenges at 10 min and the end of the fatigue period. Thus, increased intracellular concentrations of cAMP and (or) Ca2+ did not decrease fatigue in either muscle but improved recovery from fatigue in EDL and, in some conditions, in soleus.
Reading
S A
SA
Department of Human Biology and Nutritional Sciences, University of Guelph, ON, Canada.
Murrant
C L
CL
Barclay
J K
JK
D000818:Animals; D003994:Bucladesine / Q000378:metabolism / Q000494:pharmacology; D002110:Caffeine / Q000494:pharmacology; D002170:Canada; D000242:Cyclic AMP / Q000008:administration & dosage; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004558:Electric Stimulation; D005552:Forelimb / Q000033:anatomy & histology; D005947:Glucose; D018496:Hyperoxia / Q000378:metabolism / Q000503:physiopathology; D000860:Hypoxia / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects* / Q000502:physiology*; D018763:Muscle Fatigue / Q000187:drug effects* / Q000502:physiology; D018482:Muscle, Skeletal / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology*; D013997:Time Factors; D014034:Toes / Q000033:anatomy & histology; D014325:Tromethamine
C074097:Krebs-Henseleit solution; D014325:Tromethamine; D002110:Caffeine; D003994:Bucladesine; D000242:Cyclic AMP; D005947:Glucose